$HROW News

Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

Is Harrow (HROW) Below Fair Value Based On Its Sales?

Do Options Traders Know Something About Harrow Stock We Don't?

Harrow: Q3 Needs To Prove The Turnaround Is Real

Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?

BTIG Reiterates Buy on Harrow, Maintains $63 Price Target

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45

Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study

Harrow (HROW) Q2 2026 Earnings Call Transcript

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition

Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ...

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

BTIG Reiterates Buy on Harrow, Maintains $63 Price Target

Harrow Health, Inc. Q2 2026 Earnings Call Summary